MAZE
Maze Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$29.70
+7.88%0
Insider buys (3m)
32
Insider sells (3m)
-$6.1M
Net value (3m)
+5.0%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Oct 2, 2026 | Coloma Jason V · director, officer: Chief Executive Officer | Sale | 2,593 | $27 |
| Oct 2, 2026 | Coloma Jason V · director, officer: Chief Executive Officer | Sale | 31,908 | $27 |
| Oct 2, 2026 | Bernstein Harold · officer: President, R&D & CMO | M-Exempt | 16,141 | $10 |
| Oct 2, 2026 | Bernstein Harold · officer: President, R&D & CMO | Sale | 16,141 | $27 |
| Oct 1, 2026 | Dandekar Atul · officer: CSBO | M-Exempt | 7,500 | $10 |
| Oct 1, 2026 | Dandekar Atul · officer: CSBO | Sale | 7,500 | $27 |
| Sep 8, 2026 | Bernstein Harold · officer: President, R&D & CMO | Sale | 9,705 | $26 |
| Sep 4, 2026 | Courtney Phillips · officer: GC and Corp. Secretary | Sale | 1,738 | $26 |
| Sep 4, 2026 | Coloma Jason V · director, officer: Chief Executive Officer | Sale | 9,852 | $26 |
| Sep 4, 2026 | Dandekar Atul · officer: CSBO | Sale | 36 | $26 |
| Sep 4, 2026 | Dandekar Atul · officer: CSBO | Sale | 3,207 | $26 |
| Sep 4, 2026 | Dandekar Atul · officer: CSBO | Sale | 391 | $27 |
| Sep 4, 2026 | Dandekar Atul · officer: CSBO | Sale | 2,800 | $26 |
| Sep 4, 2026 | Courtney Phillips · officer: GC and Corp. Secretary | Sale | 22 | $26 |
| Sep 4, 2026 | Courtney Phillips · officer: GC and Corp. Secretary | Sale | 1,990 | $26 |
| Sep 4, 2026 | Courtney Phillips · officer: GC and Corp. Secretary | Sale | 243 | $27 |
| Sep 4, 2026 | Bernstein Harold · officer: President, R&D & CMO | Sale | 59 | $26 |
| Sep 4, 2026 | Bernstein Harold · officer: President, R&D & CMO | Sale | 5,130 | $26 |
| Sep 4, 2026 | Bernstein Harold · officer: President, R&D & CMO | Sale | 625 | $27 |
| Sep 4, 2026 | Bernstein Harold · officer: President, R&D & CMO | Sale | 4,481 | $26 |
| Sep 4, 2026 | Coloma Jason V · director, officer: Chief Executive Officer | Sale | 129 | $26 |
| Sep 4, 2026 | Coloma Jason V · director, officer: Chief Executive Officer | Sale | 11,282 | $26 |
| Sep 4, 2026 | Coloma Jason V · director, officer: Chief Executive Officer | Sale | 1,375 | $27 |
| Sep 3, 2026 | Bernstein Harold · officer: President, R&D & CMO | M-Exempt | 20,000 | $0.00 |
| Sep 3, 2026 | Bernstein Harold · officer: President, R&D & CMO | Sale | 16,141 | $26 |
| Sep 3, 2026 | Bernstein Harold · officer: President, R&D & CMO | M-Exempt | 16,141 | $10 |
| Sep 3, 2026 | Coloma Jason V · director, officer: Chief Executive Officer | M-Exempt | 50,000 | $0.00 |
| Sep 3, 2026 | Coloma Jason V · director, officer: Chief Executive Officer | Sale | 31,908 | $26 |
| Sep 3, 2026 | Coloma Jason V · director, officer: Chief Executive Officer | Sale | 2,593 | $26 |
| Sep 3, 2026 | Dandekar Atul · officer: CSBO | M-Exempt | 12,500 | $0.00 |
Institutional positioning
13F filings over the trailing two quarters
New 90Increased 123Reduced 79Sold out 41
| Filer | Action | Shares | Filed |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | Increased | 5,032,915 | Aug 14, 2026 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | Unchanged | 4,567,274 | May 15, 2026 |
| TRV GP IV, LLC | Unchanged | 4,473,958 | May 7, 2026 |
| TRV GP IV, LLC | Unchanged | 4,473,958 | Aug 10, 2026 |
| ARCH VENTURE MANAGEMENT, LLC | Unchanged | 4,120,053 | May 15, 2026 |
| ARCH Venture Management, LLC | Unchanged | 4,120,053 | Aug 14, 2026 |
| Deep Track Capital, LP | Increased | 3,732,569 | Aug 14, 2026 |
| BlackRock, Inc. | Increased | 3,502,841 | Aug 7, 2026 |
| DEEP TRACK CAPITAL, LP | Reduced | 3,477,562 | May 15, 2026 |
| Jupiter Topco LLC | New Position | 3,408,045 | Aug 14, 2026 |
| JANUS HENDERSON GROUP PLC | Reduced | 2,858,876 | May 18, 2026 |
| PARADIGM BIOCAPITAL ADVISORS LP | New Position | 2,744,399 | May 15, 2026 |
| T. Rowe Price Investment Management, Inc. | New Position | 2,603,682 | Aug 14, 2026 |
| BLACKROCK, INC. | Increased | 2,570,425 | May 13, 2026 |
| Logos Global Management LP | Increased | 1,935,000 | Aug 14, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Oct 2, 2026